---
title: "12 Health Care Stocks Moving In Wednesday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277778074.md"
description: "In Wednesday's pre-market session, Can Fite Biopharma (AMEX:CANF) saw a significant gain of 17.6%, reaching $5.88, while Evolus (NASDAQ:EOLS) rose 14.76% to $4.74. Other gainers included Reviva Pharmaceuticals (NASDAQ:RVPH) up 11.47% to $0.24, and Kala Bio (NASDAQ:KALA) up 10.92% to $0.39. Conversely, SCWorx (NASDAQ:WORX) experienced a sharp decline of 44.1% to $0.1, with Matinas BioPharma Hldgs (AMEX:MTNB) down 16.33% to $0.51. Overall, several health care stocks showed notable movements in the pre-market trading."
datetime: "2026-03-04T12:05:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277778074.md)
  - [en](https://longbridge.com/en/news/277778074.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277778074.md)
---

# 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

### Gainers

-   **Can Fite Biopharma** (AMEX:CANF) stock rose 17.6% to $5.88 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.5 million.
-   **Evolus** (NASDAQ:EOLS) stock moved upwards by 14.76% to $4.74. The market value of their outstanding shares is at $267.7 million. The company's, Q4 earnings came out yesterday.
-   **Reviva Pharmaceuticals** (NASDAQ:RVPH) stock moved upwards by 11.47% to $0.24. The market value of their outstanding shares is at $25.1 million.
-   **20/20 Biolabs** (NASDAQ:AIDX) stock rose 11.18% to $3.28. The market value of their outstanding shares is at $30.5 million.
-   **Kala Bio** (NASDAQ:KALA) stock moved upwards by 10.92% to $0.39. The company's market cap stands at $319.6 million.
-   **Medicus Pharma** (NASDAQ:MDCX) stock moved upwards by 9.52% to $1.61. The market value of their outstanding shares is at $36.3 million.

### Losers

-   **SCWorx** (NASDAQ:WORX) shares declined by 44.1% to $0.1 during Wednesday's pre-market session. The company's market cap stands at $2.8 million.
-   **Matinas BioPharma Hldgs** (AMEX:MTNB) stock fell 16.33% to $0.51. The company's market cap stands at $3.8 million.
-   **XORTX Therapeutics** (NASDAQ:XRTX) stock declined by 16.24% to $0.33. The market value of their outstanding shares is at $2.7 million.
-   **Innovative Eyewear** (NASDAQ:LUCY) shares decreased by 11.51% to $1.0. The market value of their outstanding shares is at $6.0 million.
-   **Staar Surgical** (NASDAQ:STAA) shares decreased by 10.15% to $17.0. The company's market cap stands at $934.0 million. The company's, Q4 earnings came out yesterday.
-   **SILO Pharma** (NASDAQ:SILO) shares decreased by 9.93% to $0.34. The company's market cap stands at $5.1 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [RVPH.US](https://longbridge.com/en/quote/RVPH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [WORX.US](https://longbridge.com/en/quote/WORX.US.md)
- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [KALA.US](https://longbridge.com/en/quote/KALA.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)](https://longbridge.com/en/news/283014601.md)
- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)
- [BUZZ-Cancer biotech Adlai Nortye jumps after $150 mln equity financing](https://longbridge.com/en/news/282996483.md)
- [J&J first-quarter profit beats on cancer drug Darzalex demand; raises 2026 outlook](https://longbridge.com/en/news/282672407.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)